Quil-A® adjuvant

Saponin vaccine adjuvant

Quil‑A® adjuvant is a saponin adjuvant produced under GMP by Brenntag Biosector, a leader in the global vaccine adjuvants market, and purified by them through a proprietary process that ensures consistency and immunostimulatory potential.

Quil-A® adjuvant is used in a wide variety of veterinary vaccines, as well as in immunological research into human and veterinary applications [1,2]. Quil-A® adjuvant contains the water-extractable fraction of saponins from the South-American tree, Quillaja saponaria Molina.
These saponins belong to the group of triterpenoid saponins, that have a common triterpenoid backbone structure.

Saponins induce a strong adjuvant response to T-dependent as well as T-independent antigens [3]. Saponins also induce strong cytotoxic CD8+ lymphocyte responses and potentiate the response to mucosal antigens [2,3]. When combined with cholesterol and phospholipids to form ISCOMs (immunostimulatory complexes), Quil-A® adjuvant can activate both the cell‑mediated and the antibody-mediated immune responses to a broad range of viral, bacterial, parasitic and tumor antigens [4].

InvivoGen products are for research purposes only; they are not for use in humans.
Quil-A® is a trademark which belongs to Brenntag Biosector A/S and which is registered in a large number of countries and regions worldwide.


CAS number: 8047-15-2
Dry matter: ≥95%
Product is not sterile
Quil-A® adjuvant should only be injected subcutaneously or intramuscularly.

Dosing  Guidelines
Mice: ≤15 µg/dose
Guinea pigs: ≤ 25 µg/dose
Rabbits: ≤ 50 µg/dose
Pigs: ≤300 µg/dose
Cattle: ≤750 µg/dose


• 1 g lyophilized Quil-A® adjuvant

Product is not sterile. However, prior to lyophilization Quil-A® adjuvant has been passed through a 0.22 micron filter. Hence, the product has very few colony forming units (CFU).

Quil-A® adjuvant is provided lyophilized and shipped at room temperature.
Lyophilized Quil-A® adjuvant can be stored from -25 °C to 25 °C.


1. Reed S. et al., 2013. Key roles of adjuvants in modern vaccines. Nat Med. 19(12):1597-608.
2. Singh M. & O’Hagan D., 2003. Recent advances in veterinary vaccine adjuvants. Int J Parasitol. 33:469-78.
3. Petrovsky N. & Aguilar JC., 2004. Vaccine adjuvants: Current state and future trends. Immunol Cell Biol.82(5):488-96.
4. Sun HX. et al., 2009. ISCOMs and ISOMATRIXTM. Vaccine 27(33):4388-401.


Recent articles using InvivoGen Quil-A® adjuvant


Quil-A® adjuvant

Description Saponin vaccine adjuvant
Cat. Codevac-quil
Unit Size1 g
Price For price or distributor address,
please select your country
Disclaimer: Our products are provided for research purpose only. Commercial applications may require licensing from third parties.
Note that the sequence of available ORFs provided by InvivoGen can differ from a given reference Genbank record due to genetic variations and/or alternative splicing. Customers should verify that the version of a gene sold by InvivoGen is suitable for the customer needs.
Copyrights © 2011-2016 InvivoGen. All Rights Reserved. Reproduction of any materials from this site is strictly forbidden without permission for commercial use. Nonprofit use for non-commercial research and educational purposes is permitted, citation should include the URL "www.invivogen.com".